{"nctId":"NCT00684177","briefTitle":"Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","startDateStruct":{"date":"2008-05"},"conditions":["Skin Infections, Bacterial"],"count":508,"armGroups":[{"label":"Retapamulin Ointment, 1%","type":"EXPERIMENTAL","interventionNames":["Drug: Retapamulin Ointment, 1%"]},{"label":"Placebo Ointment","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo ointment"]}],"interventions":[{"name":"Retapamulin Ointment, 1%","otherNames":["Retapamulin Ointment","1%"]},{"name":"Placebo ointment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* subject is aged 2 months or older\n* subject has secondarily-infected traumatic lesion (laceration, sutured wound or abrasion)\n* negative urine pregnancy test\n* subject has total skin infection rating scale score of at least 8, including pus/exudate score of at least 3\n* subject and/or parent/legal guardian is willing and able to comply with protocol\n* subject or parent/legal guardian has given written informed consent or assent as applicable\n\nExclusion criteria:\n\n* previous hypersensitivity to pleuromutilin\n* secondarily-infected animal/human bite or puncture wound\n* subject has an abscess\n* chronic ulcerative lesion\n* underlying skin disease\n* systemic signs and symptoms of infection\n* infection not appropriately treated with topical antibiotic\n* infection requires surgical intervention prior to or during study\n* subject received systemic antibacterial or steroid, or topical therapeutic agent within 24 hours of entry into study\n* serious underlying disease\n* subject pregnant, breast feeding or planning a pregnancy, or unacceptable method of contraception\n* other investigational drug within 30 days of study entry\n* subject previously enrolled in this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population","description":"\"Clinical Success\" at follow-up was defined as \"Resolution of clinically meaningful signs and symptoms of infection recorded at baseline including a pus/exudate Skin Infection Rating Scale (SIRS) score of \"0\". Clinical response at follow-up was classified as \"Clinical Failure\" for all other cases. The SIRS consists of seven items (pus/exudates, crusting, erythema/inflammation, tissue warmth, tissue edema, itching and pain). Each item has a score ranging from 0 to 6 (0=absent, 6=severe). The SIRS total score was calculated as the sum of the scores of all 7 SIRS items.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Intent-to-Treat Bacteriology (ITTB) Subset of the Primary Efficacy Population","description":"\"Clinical Success\" at follow-up was defined as \"Resolution of clinically meaningful signs and symptoms of infection recorded at baseline including a pus/exudate Skin Infection Rating Scale (SIRS) score of \"0\". Clinical response at follow-up was classified as \"Clinical Failure\" for all other cases. The SIRS consists of seven items (pus/exudates, crusting, erythema/inflammation, tissue warmth, tissue edema, itching and pain). Each item has a score ranging from 0 to 6 (0=absent, 6=severe). The SIRS total score was calculated as the sum of the scores of all 7 SIRS items.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Microbiological Success and Failure at Follow-up (7-9 Days Post Therapy)","description":"The \"by pathogen\" microbiological outcome was determined by comparing the baseline culture results to those at follow-up. The \"by subject\" microbiological response was \"Microbiological Success\" if the microbiological outcomes for all baseline pathogens (bps) belong to \"Eradication\" (elimination of bps), \"Presumed Eradication\" (clinical outcome was success; no culture was obtained due to lack of culturable material), or \"Colonization\" (previously unidentified pathogen is identified at end of therapy in participant who is resolved/improved); otherwise, response was \"Microbiological Failure\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Clinical Outcome at End of Therapy (2-4 Days Post Therapy)","description":"Clinical outcome is determined by the investigator based on signs and symptoms (S/S) at the end of therapy evaluation. The 4 clincal outcome categories are: clinical success, resolution of clinically meaningful S/S of infection recorded at baseline (BL), including a pus/exudates score of 0; clinical improvement, improvement of S/S of infection recorded at BL to such an extent that no further antimicrobial therapy is necessary; clinical failure, insufficient improvement of deterioration of S/S of infection recorded at BL such that additional antibiotic therapy is required; unable to determine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Baseline Pathogens With the Indicated Microbiological Outcome at End of Therapy (2-4 Days Post Therapy)","description":"The \"by pathogen\" microbiological outcome was determined by comparing the baseline culture results to those at follow-up. The results presented below pooled all baseline pathogens (bps). Eradication: elimination of bps. Presumed Eradication: clinical outcome was success; no culture was obtained due to lack of culturable material. Presumed Improvement: clinical outcome was improvement such that no culture was obtained due to lack of culturable material. Persistence: bps still present. Presumed persistence: clinical failure and no culture was obtained.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Therapeutic Success and Failure at Follow-up (7-9 Days Post Therapy)","description":"\"Therapeutic Success (Succ)\" was referred to as both \"Clinical Succ\" and \"Microbiological (Micro) Succ\" at Follow-up. \"Clinical Succ\" was the \"Resolution of baseline signs/symptoms of infection with a pus score of \"0.\" A participant was \"Micro Succ\" if the micro outcome for all baseline pathogens (bps) belonged to \"Eradication\" (elimination of bps), \"Presumed Eradication\" (clinical outcome is success; no culturable material), or \"Colonization\" (new pathogen is identified at end of therapy in participants who are resolved/improved). All other combinations were deemed \"Therapeutic Failures.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":342},"commonTop":["Application site pain","Condition aggravated","Pyrexia"]}}}